sigma pharmaceuticals plc Company Information
Company Number
01561802
Website
www.sigmaplc.comRegistered Address
fifth floor watson house, 54-60 baker street, london, W1U 7BU
Industry
Wholesale of pharmaceutical goods
Telephone
08003584427
Next Accounts Due
February 2025
Group Structure
View All
Shareholders
orion holdings (uk) limited 33.3%
bharat kumar shah 22.2%
View Allsigma pharmaceuticals plc Estimated Valuation
Pomanda estimates the enterprise value of SIGMA PHARMACEUTICALS PLC at £268.7m based on a Turnover of £248m and 1.08x industry multiple (adjusted for size and gross margin).
sigma pharmaceuticals plc Estimated Valuation
Pomanda estimates the enterprise value of SIGMA PHARMACEUTICALS PLC at £155.4m based on an EBITDA of £16m and a 9.7x industry multiple (adjusted for size and gross margin).
sigma pharmaceuticals plc Estimated Valuation
Pomanda estimates the enterprise value of SIGMA PHARMACEUTICALS PLC at £78.5m based on Net Assets of £37.8m and 2.08x industry multiple (adjusted for liquidity).
Sigma Pharmaceuticals Plc AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Sigma Pharmaceuticals Plc Overview
Sigma Pharmaceuticals Plc is a live company located in london, W1U 7BU with a Companies House number of 01561802. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in May 1981, it's largest shareholder is orion holdings (uk) limited with a 33.3% stake. Sigma Pharmaceuticals Plc is a mature, mega sized company, Pomanda has estimated its turnover at £248m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Sigma Pharmaceuticals Plc Health Check
Pomanda's financial health check has awarded Sigma Pharmaceuticals Plc a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 4 areas for improvement. Company Health Check FAQs
6 Strong
2 Regular
4 Weak
Size
annual sales of £248m, make it larger than the average company (£24.8m)
£248m - Sigma Pharmaceuticals Plc
£24.8m - Industry AVG
Growth
3 year (CAGR) sales growth of 4%, show it is growing at a similar rate (4.8%)
4% - Sigma Pharmaceuticals Plc
4.8% - Industry AVG
Production
with a gross margin of 19.3%, this company has a higher cost of product (25.1%)
19.3% - Sigma Pharmaceuticals Plc
25.1% - Industry AVG
Profitability
an operating margin of 6.1% make it more profitable than the average company (3.7%)
6.1% - Sigma Pharmaceuticals Plc
3.7% - Industry AVG
Employees
with 430 employees, this is above the industry average (38)
430 - Sigma Pharmaceuticals Plc
38 - Industry AVG
Pay Structure
on an average salary of £33k, the company has a lower pay structure (£73.6k)
£33k - Sigma Pharmaceuticals Plc
£73.6k - Industry AVG
Efficiency
resulting in sales per employee of £576.8k, this is equally as efficient (£671k)
£576.8k - Sigma Pharmaceuticals Plc
£671k - Industry AVG
Debtor Days
it gets paid by customers after 85 days, this is later than average (63 days)
85 days - Sigma Pharmaceuticals Plc
63 days - Industry AVG
Creditor Days
its suppliers are paid after 60 days, this is slower than average (31 days)
60 days - Sigma Pharmaceuticals Plc
31 days - Industry AVG
Stock Days
it holds stock equivalent to 45 days, this is less than average (64 days)
45 days - Sigma Pharmaceuticals Plc
64 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 3 weeks, this is less cash available to meet short term requirements (9 weeks)
3 weeks - Sigma Pharmaceuticals Plc
9 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 63.1%, this is a higher level of debt than the average (57.1%)
63.1% - Sigma Pharmaceuticals Plc
57.1% - Industry AVG
sigma pharmaceuticals plc Credit Report and Business Information
Sigma Pharmaceuticals Plc Competitor Analysis
Perform a competitor analysis for sigma pharmaceuticals plc by selecting its closest rivals and benchmarking them against 12 key performance metrics.
sigma pharmaceuticals plc Ownership
SIGMA PHARMACEUTICALS PLC group structure
Sigma Pharmaceuticals Plc has no subsidiary companies.
Ultimate parent company
SIGMA PHARMACEUTICALS PLC
01561802
sigma pharmaceuticals plc directors
Sigma Pharmaceuticals Plc currently has 7 directors. The longest serving directors include Mr Hatul Shah (Mar 2011) and Mr Bhavin Shah (Mar 2011).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mr Hatul Shah | United Kingdom | 45 years | Mar 2011 | - | Director |
Mr Bhavin Shah | United Kingdom | 40 years | Mar 2011 | - | Director |
Mr Rajiv Shah | England | 39 years | Mar 2011 | - | Director |
Mr Paras Shah | United Kingdom | 36 years | Nov 2014 | - | Director |
Mr Rajesh Haria | England | 59 years | Apr 2020 | - | Director |
Mr James Moir | United Kingdom | 59 years | Apr 2022 | - | Director |
Mr Mark Hampton | United Kingdom | 59 years | Jul 2022 | - | Director |
SIGMA PHARMACEUTICALS PLC financials
Sigma Pharmaceuticals Plc's latest turnover from August 2023 is £248 million and the company has net assets of £37.8 million. According to their latest financial statements, Sigma Pharmaceuticals Plc has 430 employees and maintains cash reserves of £2.6 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Aug 2023 | Aug 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 | Aug 2015 | Aug 2014 | Aug 2013 | Aug 2012 | Aug 2011 | Aug 2010 | Aug 2009 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | 248,028,130 | 207,670,692 | 214,717,036 | 220,380,612 | 227,012,613 | 248,481,927 | 253,479,235 | 240,442,000 | 241,824,000 | 232,783,105 | 214,903,208 | 177,124,619 | 213,017,541 | 218,212,601 | 165,070,566 |
Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost Of Sales | 200,130,938 | 174,936,157 | 186,894,646 | 194,555,849 | 199,533,212 | 222,688,317 | 226,129,834 | 215,102,000 | 219,053,000 | 210,586,737 | 193,652,189 | 159,389,399 | 191,960,830 | 198,592,923 | 148,655,260 |
Gross Profit | 47,897,192 | 32,734,535 | 27,822,390 | 25,824,763 | 27,479,401 | 25,793,610 | 27,349,401 | 25,340,000 | 22,771,000 | 22,196,368 | 21,251,019 | 17,735,220 | 21,056,711 | 19,619,678 | 16,415,306 |
Admin Expenses | 32,683,947 | 27,376,668 | 26,856,683 | 25,690,529 | 25,794,797 | 24,958,575 | 22,963,674 | 22,986,000 | 20,160,000 | 19,541,674 | 18,883,230 | 16,026,410 | 18,510,375 | 16,847,366 | 14,397,150 |
Operating Profit | 15,213,245 | 5,357,867 | 965,707 | 134,234 | 1,684,604 | 835,035 | 4,385,727 | 2,354,000 | 2,611,000 | 2,654,694 | 2,367,789 | 1,708,810 | 2,546,336 | 2,772,312 | 2,018,156 |
Interest Payable | 2,165,088 | 778,071 | 676,869 | 759,948 | 841,216 | 769,292 | 769,338 | 752,000 | 637,000 | 740,645 | 634,709 | 678,862 | 670,692 | 666,547 | 723,099 |
Interest Receivable | 0 | 266,910 | 18,854 | 39,029 | 18,100 | 15,238 | 19,078 | 33,000 | 15,000 | 18,696 | 7,220 | 14,685 | 72 | 21 | 2,421 |
Pre-Tax Profit | 12,783,173 | 4,846,706 | 550,327 | -806,394 | 746,714 | 78,821 | 3,635,467 | 1,635,000 | 1,989,000 | 1,932,745 | 1,740,300 | 1,055,358 | 1,875,716 | 2,105,786 | 1,297,478 |
Tax | -2,847,150 | -297,802 | 60,869 | 149,270 | -477,476 | 547,878 | -763,064 | -303,000 | -180,000 | -435,383 | -850,704 | -269,536 | -558,748 | -660,987 | -460,640 |
Profit After Tax | 9,936,023 | 4,548,904 | 611,196 | -657,124 | 269,238 | 626,699 | 2,872,403 | 1,332,000 | 1,809,000 | 1,497,362 | 889,596 | 785,822 | 1,316,968 | 1,444,799 | 836,838 |
Dividends Paid | 672,225 | 0 | 0 | 0 | 0 | 0 | 9,000 | 450,000 | 968,000 | 0 | 0 | 0 | 0 | 900,000 | 0 |
Retained Profit | 9,263,798 | 4,548,904 | 611,196 | -657,124 | 269,238 | 626,699 | 2,863,403 | 882,000 | 841,000 | 1,497,362 | 889,596 | 785,822 | 1,316,968 | 544,799 | 836,838 |
Employee Costs | 14,174,354 | 12,834,964 | 12,870,498 | 10,844,769 | 10,721,920 | 10,631,968 | 10,256,162 | 9,893,000 | 8,273,000 | 7,762,052 | 7,144,114 | 6,481,566 | 6,241,846 | 5,794,329 | 5,298,788 |
Number Of Employees | 430 | 391 | 360 | 339 | 311 | 308 | 328 | 318 | 306 | 234 | 270 | 260 | 248 | 244 | 219 |
EBITDA* | 16,021,982 | 6,106,877 | 1,717,950 | 1,017,760 | 2,505,854 | 1,779,866 | 5,367,281 | 2,590,000 | 2,827,000 | 2,865,019 | 2,624,065 | 2,002,491 | 2,809,641 | 2,986,841 | 2,206,456 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Aug 2023 | Aug 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 | Aug 2015 | Aug 2014 | Aug 2013 | Aug 2012 | Aug 2011 | Aug 2010 | Aug 2009 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 8,698,611 | 8,789,831 | 8,825,089 | 8,720,499 | 9,071,637 | 13,898,258 | 9,012,434 | 3,036,000 | 2,426,000 | 2,534,805 | 581,778 | 693,288 | 600,544 | 479,270 | 440,006 |
Intangible Assets | 0 | 264,984 | 0 | 0 | 301,931 | 476,931 | 705,603 | 886,000 | 140,000 | 33,159 | 38,313 | 87,810 | 150,396 | 213,521 | 169,961 |
Investments & Other | 180,000 | 282,000 | 282,000 | 282,000 | 282,000 | 282,000 | 282,000 | 282,000 | 282,000 | 282,000 | 282,000 | 282,000 | 327,000 | 327,000 | 45,000 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 4,953,524 | 4,497,000 | 4,196,000 | 3,858,155 | 7,049,377 | 8,900,549 | 10,367,264 | 0 | 934,988 |
Total Fixed Assets | 8,878,611 | 9,336,815 | 9,107,089 | 8,720,499 | 9,373,568 | 14,375,189 | 14,953,561 | 8,701,000 | 7,044,000 | 6,708,119 | 7,951,468 | 9,963,647 | 11,445,204 | 1,019,791 | 1,589,955 |
Stock & work in progress | 25,000,969 | 24,114,827 | 32,078,193 | 36,285,620 | 42,977,739 | 33,002,558 | 36,279,451 | 38,949,000 | 34,502,000 | 31,603,367 | 33,035,569 | 37,508,005 | 42,362,306 | 45,066,397 | 35,541,591 |
Trade Debtors | 58,293,563 | 53,880,974 | 49,183,110 | 48,671,821 | 47,211,314 | 47,199,421 | 46,624,731 | 45,406,000 | 50,814,000 | 47,626,569 | 45,237,669 | 35,616,776 | 35,011,329 | 40,864,122 | 34,593,209 |
Group Debtors | 3,438,117 | 3,382,954 | 4,757,316 | 7,258,652 | 7,401,790 | 0 | 2,789,987 | 2,848,000 | 2,911,000 | 6,208,201 | 4,595,861 | 3,596,817 | 2,170,489 | 1,559,147 | 1,578,615 |
Misc Debtors | 4,178,983 | 2,705,407 | 2,754,422 | 1,103,345 | 2,632,826 | 5,117,495 | 2,007,883 | 1,664,000 | 981,000 | 281,372 | 440,967 | 730,332 | 3,561,142 | 1,319,208 | 969,039 |
Cash | 2,598,694 | 3,153,341 | 1,522,859 | 5,690,826 | 1,343,170 | 2,156,418 | 3,891,201 | 4,534,000 | 1,882,000 | 9,125,977 | 5,805,732 | 3,407,341 | 2,182,493 | 1,644,132 | 2,230,523 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total current assets | 93,510,326 | 87,237,503 | 90,295,900 | 99,010,264 | 101,566,839 | 87,475,892 | 91,593,253 | 93,401,000 | 91,090,000 | 94,845,486 | 89,115,798 | 80,859,271 | 85,287,759 | 90,453,006 | 74,912,977 |
total assets | 102,388,937 | 96,574,318 | 99,402,989 | 107,730,763 | 110,940,407 | 101,851,081 | 106,546,814 | 102,102,000 | 98,134,000 | 101,553,605 | 97,067,266 | 90,822,918 | 96,732,963 | 91,472,797 | 76,502,932 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 30,132,528 | 31,086,000 | 24,813,000 | 30,499,940 | 25,586,776 | 22,969,582 | 24,264,046 | 27,408,761 | 20,916,515 |
Bank loan | 96,107 | 32,413,345 | 38,404,001 | 39,250,896 | 37,774,910 | 0 | 1,672,980 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 32,921,682 | 29,219,516 | 32,082,748 | 30,975,544 | 38,934,799 | 31,593,344 | 34,942,444 | 35,236,000 | 38,714,000 | 33,845,475 | 34,525,910 | 30,900,476 | 32,906,038 | 36,031,269 | 29,627,611 |
Group/Directors Accounts | 302,828 | 143,421 | 0 | 0 | 0 | 0 | 500 | 7,000 | 4,000 | 0 | 6,428 | 6,428 | 1,454 | 296 | 296 |
other short term finances | 230,802 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 54,319 | 227,826 | 277,766 | 374,761 | 367,397 | 74,710 | 15,000 | 13,000 | 15,871 | 16,869 | 12,115 | 0 | 2,028 | 26,418 |
other current liabilities | 8,931,928 | 6,220,237 | 4,228,353 | 10,477,605 | 5,508,302 | 35,493,637 | 3,580,920 | 3,541,000 | 4,134,000 | 8,216,749 | 6,053,053 | 4,775,974 | 5,221,236 | 4,009,617 | 2,454,037 |
total current liabilities | 42,483,347 | 68,050,838 | 74,942,928 | 80,981,811 | 82,592,772 | 67,454,378 | 70,404,082 | 69,885,000 | 67,678,000 | 72,578,035 | 66,189,036 | 58,664,575 | 62,392,774 | 67,451,971 | 53,024,877 |
loans | 22,110,587 | 0 | 0 | 1,091,158 | 3,096,014 | 6,694,172 | 4,999,075 | 1,562,000 | 972,000 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 29,782 | 22,057 | 82,750 | 310,579 | 549,007 | 842,581 | 274,963 | 65,000 | 17,000 | 19,487 | 34,712 | 33,130 | 0 | 0 | 2,028 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,000,798 | 6,001,597 | 9,002,395 | 0 | 0 |
other liabilities | 0 | 0 | 424,792 | 0 | 0 | 0 | 0 | 356,000 | 115,000 | 445,508 | 829,508 | 0 | 0 | 0 | 0 |
provisions | 0 | 0 | 0 | 121,738 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 22,140,369 | 22,057 | 507,542 | 606,448 | 1,548,007 | 3,347,086 | 5,274,038 | 1,983,000 | 1,104,000 | 464,995 | 3,865,018 | 6,034,727 | 9,002,395 | 0 | 2,028 |
total liabilities | 64,623,716 | 68,072,895 | 75,450,470 | 81,588,259 | 84,140,779 | 70,801,464 | 75,678,120 | 71,868,000 | 68,782,000 | 73,043,030 | 70,054,054 | 64,699,302 | 71,395,169 | 67,451,971 | 53,026,905 |
net assets | 37,765,221 | 28,501,423 | 23,952,519 | 26,142,504 | 26,799,628 | 31,049,617 | 30,868,694 | 30,234,000 | 29,352,000 | 28,510,575 | 27,013,212 | 26,123,616 | 25,337,794 | 24,020,826 | 23,476,027 |
total shareholders funds | 37,765,221 | 28,501,423 | 23,952,519 | 26,142,504 | 26,799,628 | 31,049,617 | 30,868,694 | 30,234,000 | 29,352,000 | 28,510,575 | 27,013,212 | 26,123,616 | 25,337,794 | 24,020,826 | 23,476,027 |
Aug 2023 | Aug 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 | Aug 2015 | Aug 2014 | Aug 2013 | Aug 2012 | Aug 2011 | Aug 2010 | Aug 2009 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | |||||||||||||||
Operating Profit | 15,213,245 | 5,357,867 | 965,707 | 134,234 | 1,684,604 | 835,035 | 4,385,727 | 2,354,000 | 2,611,000 | 2,654,694 | 2,367,789 | 1,708,810 | 2,546,336 | 2,772,312 | 2,018,156 |
Depreciation | 808,737 | 749,010 | 752,243 | 581,595 | 646,250 | 769,831 | 786,547 | 172,000 | 183,000 | 185,171 | 192,245 | 231,095 | 200,180 | 158,089 | 145,175 |
Amortisation | 0 | 0 | 0 | 301,931 | 175,000 | 175,000 | 195,007 | 64,000 | 33,000 | 25,154 | 64,031 | 62,586 | 63,125 | 56,440 | 43,125 |
Tax | -2,847,150 | -297,802 | 60,869 | 149,270 | -477,476 | 547,878 | -763,064 | -303,000 | -180,000 | -435,383 | -850,704 | -269,536 | -558,748 | -660,987 | -460,640 |
Stock | 886,142 | -7,963,366 | -4,207,427 | -6,692,119 | 9,975,181 | -3,276,893 | -2,669,549 | 4,447,000 | 2,898,633 | -1,432,202 | -4,472,436 | -4,854,301 | -2,704,091 | 9,524,806 | 35,541,591 |
Debtors | 5,941,328 | 3,274,487 | -338,970 | -212,112 | 4,929,014 | -4,059,209 | 1,961,125 | -4,487,000 | 927,703 | 650,423 | 8,479,400 | -2,265,750 | 7,367,747 | 5,666,626 | 38,075,851 |
Creditors | 3,702,166 | -2,863,232 | 1,107,204 | -7,959,255 | 7,341,455 | -3,349,100 | -293,556 | -3,478,000 | 4,868,525 | -680,435 | 3,625,434 | -2,005,562 | -3,125,231 | 6,403,658 | 29,627,611 |
Accruals and Deferred Income | 2,711,691 | 1,991,884 | -6,249,252 | 4,969,303 | -29,985,335 | 31,912,717 | 39,920 | -593,000 | -4,082,749 | -837,102 | -1,723,720 | -3,446,060 | 10,214,014 | 1,555,580 | 2,454,037 |
Deferred Taxes & Provisions | 0 | 0 | -121,738 | 121,738 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | 12,761,219 | 9,626,606 | 1,061,430 | 5,203,047 | -35,519,697 | 38,227,463 | 5,059,005 | -1,744,000 | -393,560 | 1,693,878 | -331,889 | 3,401,384 | 4,676,020 | -4,906,340 | -39,789,978 |
Investing Activities | |||||||||||||||
capital expenditure | -6,837,361 | -1,806,000 | -215,000 | -2,158,198 | -95,269 | -316,231 | -319,755 | -301,870 | -33,578 | ||||||
Change in Investments | -102,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -45,000 | 0 | 282,000 | 45,000 |
cash flow from investments | -6,837,361 | -1,806,000 | -215,000 | -2,158,198 | -95,269 | -271,231 | -319,755 | -583,870 | -78,578 | ||||||
Financing Activities | |||||||||||||||
Bank loans | -32,317,238 | -5,990,656 | -846,895 | 1,475,986 | 37,774,910 | -1,672,980 | 1,672,980 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 159,407 | 143,421 | 0 | 0 | 0 | -500 | -6,500 | 3,000 | 4,000 | -6,428 | 0 | 4,974 | 1,158 | 0 | 296 |
Other Short Term Loans | 230,802 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 22,110,587 | 0 | -1,091,158 | -2,004,856 | -3,598,158 | 1,695,097 | 3,437,075 | 590,000 | 972,000 | 0 | 0 | 0 | 0 | 0 | 0 |
Hire Purchase and Lease Commitments | -46,594 | -234,200 | -277,769 | -335,423 | -286,210 | 860,305 | 269,673 | 50,000 | -5,358 | -16,223 | 6,336 | 45,245 | -2,028 | -26,418 | 28,446 |
other long term liabilities | 0 | -424,792 | 424,792 | 0 | 0 | 0 | -356,000 | 241,000 | -330,508 | -384,000 | 829,508 | 0 | 0 | 0 | 0 |
share issue | |||||||||||||||
interest | -2,165,088 | -511,161 | -658,015 | -720,919 | -823,116 | -754,054 | -750,260 | -719,000 | -622,000 | -721,949 | -627,489 | -664,177 | -670,620 | -666,526 | -720,678 |
cash flow from financing | -12,028,124 | -7,017,388 | -5,250,226 | -1,585,212 | 28,548,199 | -317,908 | 2,038,259 | 165,000 | 18,559 | -1,128,599 | 208,355 | -613,958 | -671,490 | -692,944 | 21,947,253 |
cash and cash equivalents | |||||||||||||||
cash | -554,647 | 1,630,482 | -4,167,967 | 4,347,656 | -813,248 | -1,734,783 | -642,799 | 2,652,000 | -7,243,977 | 3,320,245 | 2,398,391 | 1,224,848 | 538,361 | -586,391 | 2,230,523 |
overdraft | 0 | 0 | 0 | 0 | 0 | -30,132,528 | -953,472 | 6,273,000 | -5,686,940 | 4,913,164 | 2,617,194 | -1,294,464 | -3,144,715 | 6,492,246 | 20,916,515 |
change in cash | -554,647 | 1,630,482 | -4,167,967 | 4,347,656 | -813,248 | 28,397,745 | 310,673 | -3,621,000 | -1,557,037 | -1,592,919 | -218,803 | 2,519,312 | 3,683,076 | -7,078,637 | -18,685,992 |
P&L
August 2023turnover
248m
+19%
operating profit
15.2m
+184%
gross margin
19.4%
+22.51%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
August 2023net assets
37.8m
+0.33%
total assets
102.4m
+0.06%
cash
2.6m
-0.18%
net assets
Total assets minus all liabilities
sigma pharmaceuticals plc company details
company number
01561802
Type
Public limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
incorporation date
May 1981
age
43
accounts
Group
ultimate parent company
previous names
roxburghe exports limited (November 1986)
incorporated
UK
address
fifth floor watson house, 54-60 baker street, london, W1U 7BU
last accounts submitted
August 2023
sigma pharmaceuticals plc Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 18 charges/mortgages relating to sigma pharmaceuticals plc. Currently there are 2 open charges and 16 have been satisfied in the past.
sigma pharmaceuticals plc Companies House Filings - See Documents
date | description | view/download |
---|